Plasma concentrations soluble ST2 and сardiac dysfunction in patients with essential hypertension

Main Article Content

D. A. Bahrij
O. L. Starzhynska
V. M. Zhebel


The aim – to determine the place of soluble ST2 (sST2) as a possible biomarker of remodeling and heart dysfunction in patients with essential hypertension of varying severity.
Materials and methods. Examined 150 men with confirmed essential hypertension (EН) of varying severity, including 50 people with EН complicated by heart failure (HF) IIA stage according to the classification of UAHF (groups were representative by age, mean age 50.17±0.48 y.о.), 70 men in the control group (mean age 48.82±0.78 y.о.) The following inclusion criteria were used: age 40 to 60 years, male, verified diagnosis of EH. The structure and function of the heart were studied using echocardiography with Doppler. The serum level of sST2 was determined by immuno assay.
Results and discussion. The serum level of sST2 in patients of the control group was 22.14±0.86 ng/ml. It was found, that the peptide concentration in plasma of male patients without cardiovascular disease does not significantly correlate with physical or age parameters, renal function, the condition of systemic or intracardiac hemodynamics. It was found, that for patients with EH the serum level of sST2 was significantly higher than in the control group (p<0.05). The formation of left ventricular hypertrophy (LVH) leads to a significant increase of the peptide concentration in plasma in patients with EH. However, in patients with different types of LVH – concentric and eccentric – the indicator does not differ significantly (26.87±1.04 ng/ml vs. 29.15±1.15 ng/ml, p≥0.05). It was determined, that in case of confirmed diastolic dysfunction (DD) without LVH, the level of the peptide does not increase significantly. And only in patients with a combination of DD and LVH the serum level of sST2 is significantly higher (27.64±1.17 ng/ml, p≥0.05). Also in patients with EH and left ventricular ejection fraction (LV EF) less than 40 %, the serum level of peptide is significantly higher, than in patients with preserved LV EF (25.65±1.14 ng/ml vs. 29.07±1.22 ng/ml, p≥0.01).
Conclusions. Thus, in male patients with EH of varying severity, the serum level of sST2 is significantly higher than in people without cardiovascular disease. Peptide concentration in plasma in both cases is not related to age or physical parameters. In patients with uncomplicated EH, significantly higher serum level of sST2 ​​is associated with the development of LVH, regardless of its type, and impaired diastolic function of the heart. In case of HF on the background of EH, the serum level of sST2 also is significantly higher, especially in case of the formation of systolic heart dysfunction with LV FE < 40 %.

Article Details


essential hypertension, soluble ST2, left ventricular hypertrophy


Воронков Л.Г., Амосова К.М., Дзяк Г.В. та ін. Рекомендації Асоціації кардіологів України з діагностики та лікування хронічної серцевої недостатності (2017) // Серцева недостатність та коморбідні стани. Спеціальний випуск. Додаток № 1 до журналу «Серцева недостатність та коморбідні стани».– 2017.– № 1.– C. 64.

Aimo A., Maisel A.S., Castiglione V.J. et al. sST2 for outcome prediction in acute heart failure: which is the best cutoff? // Am. Coll. Cardiol.– 2019.– Vol. 74 (3).– P. 478–479. doi:

Coglianese E.E., Larson M.G., Vasan R.S. et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study // Clin. Chem.– 2012.– Vol. 58 (12).– P. 1673–1681. doi:

Coronado M.J., Bruno K.A., Blauwet L.A. et al. Elevated sera sST2 is associated with heart failure in men ≤ 50 years old with myocarditis // J. Am. Heart Assoc.– 2019.– N 8.– P. e008968. doi:

Dieplinger B., Gegenhuber A., Kaar G. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department // Clin. Biochem.– 2010.– Vol. 43.– P. 714–719.

Fabiani I., Conte L., Pugliese N.R. et al. The integrated value of sST2 and global longitudinal strain in the early stratification of patients with severe aortic valve stenosis: a translational imaging approach // Int. J. Cardiovasc. Imaging.– 2017.– Vol. 33 (12).– P. 1915–1920. doi:

Farcaş A.D., Anton F.P., Goidescu C.M. et al. Serum soluble ST2 and diastolic dysfunction in hypertensive patients // Disease Markers.– 2017.– Article ID 2714095.– P. 1–8.

Januzzi J.L., Peacock W.F., Maisel A.S. et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study // J. Am. Coll. Cardiol.– 2007.– Vol. 50.– P. 607–613.

Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker // Nat. Rev. Drug. Discov.– 2008.– Vol. 7.– P. 827–840.

Kohli P., Bonaca M.P., Kakkar R. et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial // Clin. Chem.– 2012.– Vol. 58.– P. 257–266.

Manzano Fernandez S., Mueller T., Pascual-Figal D.A. et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction // Am. J. Cardiol.– 2011.– Vol. 107.– P. 259–267.

Manzano Fernandez S., Januzzi J.L., Pastor-Perez F.J. et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure // Cardiology.– 2012.– Vol. 122.– P. 158–166.

Maupoint J., Richard V., Vallet C. et al. Correlation between ST2 levels, Doppler echocardiographic parameters and prognosis in patients with heart failure and preserved ejection fraction // Eur. Heart J.– 2016.– Vol. 37 (Suppl. 716).– P. 3584.

Ojji D.B., Lecour S., Adeyemi O.M. et al. Soluble ST2 correlates with some indicators of right ventricular function in hypertensive heart failure // Vasc. Heal. Risk Manag.– 2017.– N 13.– P. 311–316.

Pascual-Figal D.A., Lax A., Perez-Martinez M.T. et al. Clinical relevance of sST2 in cardiac diseases // Clin. Chemistry and Laboratory Medicine (CCLM).– 2015.– Vol. 54 (1). doi:

Piper S.E., Sherwood R.A., Amin-Youssef G.F. et al. Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure // Int. J. Cardiol.– 2015.– Vol. 178.– P. 284–291. doi:

Weinberg E.O., Shimpo M., De Keulenaer G.W. et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction // Circulation.– 2002.– Vol. 106 (23).– P. 2961–2966. doi:

Whelton P. K., Carey R. M., Aronow W. S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA. Guideline for the prevention, detection, evalu­ation, and management of high blood pressure in adults: a report of the American College of Cardio­logy/American Heart Association Task Force on Clinical Practice Guidelines // Hypertension.– 2018.– Vol. ­71 (6).– P. e13–e115.

Xanthakis V., Larson M.G., Wollert K.C. et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening // J. Am. Heart Assoc.– 2013.– Vol. 2 (6).– P. e000399. doi:

Yancy C.W., Jessup M., Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America // Circulation.– 2017.– Vol. 136.– P. 137–161. doi:

Zile M.R., Baicu C.F., Ikonomidis J.S. et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin // Circulation. – 2015.– Vol. 131 (14).– P. 1247–1259. doi: